RepliCel Life Sciences Inc. (RP.V)

0.0550 0.0000 (0.00%) As of 03:56PM EDT. Market open.

RepliCel Life Sciences Inc.

570 Granville Street
Suite 900
Vancouver, BC V6C 3P1
Canada
604 248 8730
https://www.replicel.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Andrew Schutte	President, CEO & Director	8.92k	N/A	1990
Dr. Kevin John McElwee Ph.D.	Co-Founder & Chief Scientific Officer	30k	N/A	1970
Mr. Ben Austring	Chief Legal Officer, Corporate Secretary & COO	14.5k	N/A	N/A
Dr. Rolf Hoffmann M.D.	Chief Medical Officer & Member of Clinical Advisory Board	N/A	N/A	1962
Mr. David Kwok CPA	Chief Financial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. The company was founded in 2006 and is headquartered in Vancouver, Canada.

Corporate governance

RepliCel Life Sciences Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.